BD has entered into a definitive agreement to purchase a developer of anti-needlestick devices for prefilled syringes, Safety Syringes.
The acquisition will enable BD to provide Safety Syringe’s UltraSafe Passive products to any prefillable syringe customer.
BD executive vice president William Kozy said developments for parenteral drug delivery systems continue to be a part of the company’s long-term strategy.
"This acquisition is intended to provide our BD Medical – Pharmaceutical Systems unit with additional safety features for prefillable syringes, helping to protect against accidental needlesticks by providing safer injections for healthcare workers and end users," Kozy added.
UltraSafe Passive products, which are specifically designed for prefillable syringes, uses passive protection to provide a drug delivery system with a safety guard that passively (automatically) locks into place, delivering easy-to-use injury protection and safety.
BD Medical- pharmaceutical systems president Claude Dartiguelongue said, "We believe BD’s prefillable syringe expertise, combined with Safety Syringes’ product portfolio and device development expertise, will enable new and innovative safety technology development to prepare the next generation of safety-engineered prefillable syringes."
The terms of BD’s deal with Safety Syringes have not been disclosed.
The acquisition, which is expected to close by the end of BD’s fiscal year 2012, is subject to the satisfaction of regulatory customary closing conditions.